---
title: "Stoke Therapeutics, Inc. (STOK.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/STOK.US/overview.md"
symbol: "STOK.US"
name: "Stoke Therapeutics, Inc."
parent: "https://longbridge.com/zh-HK/quote/STOK.US.md"
datetime: "2026-04-05T00:55:44.109Z"
locales:
  - [en](https://longbridge.com/en/quote/STOK.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/STOK.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/STOK.US/overview.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/STOK.US/overview.md) | [简体中文](https://longbridge.com/zh-CN/quote/STOK.US/overview.md)


# Stoke Therapeutics, Inc. (STOK.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | Biotechnology |
| 交易所 | US Market |
| 地址 | 45 Wiggins Avenue, Bedford, Massachusetts, United States |
| 官網 | [www.stoketherapeutics.com](https://www.stoketherapeutics.com) |

## 公司簡介

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials.

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Ian F. Smith | CEO & Director |
| Arthur O. Tzianabos | Chairman of the Board |
| Adrian R. Krainer | Co-Founder & Independent Director |
| Thomas Edward Leggett | Chief Financial Officer |
| Edward M. Kaye | Advisor & Director |
| Barry S. Ticho | Chief Medical Officer |
| Arthur A. Levin | Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| FMR LLC | 9.47% | 2025-12-31 |
| RTW Investments, LP | 9.38% | 2025-12-31 |
| Lynx1 Capital Management LP | 9.14% | 2025-12-31 |
| BlackRock, Inc. | 8.81% | 2025-12-31 |
| Redmile Group, LLC | 6.82% | 2025-12-31 |
| Morgan Stanley | 5.95% | 2025-12-31 |
| Baker Bros. Advisors LP | 5.64% | 2025-12-31 |
| The Toronto-Dominion Bank | 5.36% | 2025-12-31 |
| Cowen Inc. | 5.36% | 2025-09-30 |
| The Vanguard Group, Inc. | 5.32% | 2025-12-31 |

## 業務構成

| 業務線 | 營收 | 佔比 |
|---------|---------|-------|
| Pharmaceuticals | 184420000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Stoke Therapeutics, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Pharmaceuticals",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地區分佈

| 地區 | 營收 | 佔比 |
|--------|---------|-------|
| North America | 184420000 | 100% |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**